Apellis reports preliminary 2025 U.S. net product revenues of $689M; cash $466M; SYFOVRE injections up 17%

Apellis Pharmaceuticals, Inc.

Full-year 2025 preliminary U.S. net product revenues: SYFOVRE $587M, EMPAVELI $102M, total $689M.
SYFOVRE total injection demand grew 17% YoY; ~60% market share in geographic atrophy; prefilled syringe submission planned 1H 2026.
EMPAVELI C3G/IC-MPGN launch: 267 patient start forms in 2025, >5% market penetration; 95% payer coverage.
Cash and cash equivalents ~$466M at Dec 31, 2025; company expects to fund operations to profitability.
Pivotal trials initiated for EMPAVELI in FSGS and DGF; IND for APL-9099 (FcRn) planned 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.